EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer

Yuan Li, Weili Zhang, Jie Du, Jinlong Hu, Ruixi Hu, Ziyang Zeng, E-Er-Man-Bie-Ke Jin-Si-Han, Shaopu Lian, Hao Wang, Yunfeng Li, Zhizhong Pan, Cheng Feng und 2 weitere

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01064-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Yuan Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinica…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Neoadjuvant Therapy, Microsatellite Instability. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant immunotherapy with programmed death-ligand 1 blockade for colon cancer, especially for mismatch repair-deficient (dMMR)/high microsatellite instability (MSI-H) colon cancer, has gained considerable attention recently. OBJECTIVE: This study aimed to assess the safety and efficacy of neoadjuvant subcutaneous envafolimab in patients with dMMR/MSI-H locally advanced colon cancer. METHODS: Patients with dMMR/MSI-H locally advanced colon cancer treated with envafolimab at Sun Yat-sen University Cancer Center and Yunnan Cancer Hospital from October 2021 to July 2023 were retrospectively reviewed and analyzed. The primary endpoint was the pathological complete response (CR) rate, and secondary endpoints were treatment-related adverse events and complete clinical response rate. RESULTS: Overall, 15 patients were analyzed. After neoadjuvant immunotherapy with envafolimab, six patients achieved a CR, with five partial responses, and four stable disease. Three patients achieving a complete clinical response chose to accept a "watch and wait" strategy, and surgery was performed in 12 patients. Postoperative pathology results revealed seven patients achieved pathological CRs, and five patients achieved tumor regression grade 2, with 66.7% of the total CR rate. The most common treatment-related adverse events were pruritus and rash (40%), with no severe cases. No recurrences occurred over a 7.9-month follow-up. CONCLUSIONS: Envafolimab yielded promising surgical outcomes and safety in dMMR/MSI-H locally advanced colon cancer, representing a promising treatment modality for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsNeoadjuvant TherapyMicrosatellite InstabilityHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultDNA Mismatch RepairInjections, Subcutaneous

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, 651 Dongfeng Road East, Guangzhou, 51006…
  • Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650000, Yunnan, People's Republic of China.
  • Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, Guangdong, People's Republic o…
  • Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650000, Yunnan, People's Republic of China. zhangxuan66@kmmu.edu.cn.

ORCID-Profile: Zhenhai Lu

Zitieren

APA

Li, Y., Zhang, W., Du, J., Hu, J., Hu, R., Zeng, Z., Jin-Si-Han, E. E., Lian, S., Wang, H., Li, Y., Pan, Z., Feng, C., Zhang, X., & Lu, Z. (2024). Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted Oncology. https://doi.org/10.1007/s11523-024-01064-x

Vancouver

Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, et al. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. Targeted Oncology. 2024. doi:10.1007/s11523-024-01064-x

BibTeX
@article{Li2024,
  author = {Li, Yuan and Zhang, Weili and Du, Jie and Hu, Jinlong and Hu, Ruixi and Zeng, Ziyang and Jin-Si-Han, E-Er-Man-Bie-Ke and Lian, Shaopu and Wang, Hao and Li, Yunfeng and Pan, Zhizhong and Feng, Cheng and Zhang, Xuan and Lu, Zhenhai},
  title = {Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01064-x}
}
Kostenlos starten →